At a glance
ClinicalIndex Comparison RecordN/ACompleted· 60 enrolled
Drug / intervention
Light therapy A (Bright) via the Re-Timer® +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Bright Light Treatment at Home to Improve Symptom Management of Fibromyalgia Syndrome
In Brief
A clinical study evaluating Light therapy A (Bright) via the Re-Timer® and Light therapy B (Dim) via the Re-Timer® for Fibromyalgia and FMS. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the effect a morning light treatment has on improving physical function, pain intensity, and pain sensitivity in people with fibromyalgia syndrome (FMS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFibromyalgia, FMS
CountriesUnited States
CollaboratorsNational Institute of Nursing Research (NINR)
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartJan 2019
Primary CompletionJul 2021
TodayJul 2026
First PostedJan 7, 2019
Enrollment StartJan 31, 2019
Primary CompletionJul 15, 2021
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 7.5 years ago
Interventions
Light therapy A (Bright) via the Re-Timer®device
Subjects will conduct light treatment in the mornings at home for one hour using Re-timer®.
Light therapy B (Dim) via the Re-Timer®device
Subjects will conduct light treatment in the mornings at home for one hour using Re-timer®.